ALNY
EquityAlnylam Pharmaceuticals, Inc.
Health Care · Biotechnology
$332.92
+332.92 (+0.00%)
Open
N/A
Day Range
$328.39 - $334.80
52W Range
$205.87 - $495.55
Volume
1M
Price History
Key Statistics
Market Cap
N/A
P/E Ratio
N/A
EPS
N/A
Dividend Yield
N/A
P/B Ratio
N/A
Payout Ratio
N/A
ROE
N/A
Debt/Equity
N/A
Latest News
Does Alnylam Pharmaceuticals (ALNY) Price Reflect Its RNAi Pipeline Potential?
Alnylam to Webcast Presentation at TD Cowen 46th Annual Health Care Conference
Alnylam Pharmaceuticals (ALNY) Reports $3B 2025 Revenue Driven by 151% TTR Franchise Surge
Analysts Trim Alnylam Pharmaceuticals, Inc. (ALNY) Targets but Keep Faith in 2026 Growth
Alnylam Pharmaceuticals Insider Sold Shares Worth $1,284,980, According to a Recent SEC Filing
Peers in Health Care
| Symbol | Name | Price | Mkt Cap | Div Yield | Change |
|---|---|---|---|---|---|
| ACAD | ACADIA Pharmaceuticals Inc. | $24.56 | N/A | - | +0.00% |
| ABT | Abbott Laboratories | $116.35 | N/A | 2.06% | +0.00% |
| ACB | Aurora Cannabis Inc. | $3.84 | N/A | - | +0.00% |
| CRSP | CRISPR Therapeutics AG | $60.14 | N/A | - | +0.00% |
| A | Agilent Technologies, Inc. | $121.38 | N/A | 0.82% | +0.00% |
| AHCO | AdaptHealth Corp. | $9.15 | N/A | - | +0.00% |
| 001540.KQ | AHN-GOOK PHA | $8,070.00 | N/A | 5.45% | +0.00% |
| ABBV | AbbVie Inc. | $232.08 | N/A | 2.87% | +0.00% |
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amyloidosis; Zilebesiran for hypertension; Cemdisiran for myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and Elebsiran for hepatitis D virus infections. In addition, the company is developing various products in Phase 2 trial, including Rapirosiran for metabolic dysfunction-associated steatohepatitis; ALN-ANG3 for diabetic kidney disease; ALN-4324 for type 2 diabetes mellitus; Mivelsiran for cerebral amyloid angiopathy, as well as in Phase 1 trial for Alzheimer's disease; and ALN-6400 for bleeding disorders. Further, it develops a range of products in Phase 1 trial, such as ALN-2232 for obesity and weight management; ALN-PNP for non-alcoholic fatty liver disease; ALN-APOC3 for dyslipidemia; ALN-CIDEB for metabolic dysfunction-associated steatohepatitis; ALN-HTT02 for Huntington's disease; ALN-5288 for Alzheimer's disease; ALN-SOD for SOD1 amyotrophic lateral sclerosis; ALN-SNCA for Parkinson's disease; AG-236 for polycythemia vera; ALN-CFB for paroxysmal nocturnal hemoglobinuria; ALN-BCAT for hepatocellular carcinoma; and ALN-4285, ALN-4915, and ALN-F1202 for healthy volunteers. The company has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.
www.alnylam.com →🐂 Bull Score
Our proprietary rating measures dividend reliability based on 6 fundamental factors including payout sustainability, financial strength, and cash flow coverage.
Very Risky
Bull Score
Dividend Safety
Assessment based on payout ratio, debt levels, profit margins, and dividend growth track record.
Borderline
Based on 4 fundamental factors
Analysis Tools
Share
No dividend data available for ALNY
🐂 Bull Score
Our proprietary rating measures dividend reliability based on 6 fundamental factors including payout sustainability, financial strength, and cash flow coverage.
Very Risky
Bull Score
Dividend Safety
Assessment based on payout ratio, debt levels, profit margins, and dividend growth track record.
Borderline
Based on 4 fundamental factors
Loading financial data...
Revenue & Earnings
No financial statement data available for ALNY.